Division of Bioton SA
Latest From BioPartners GmbH
Positive opinions from Europe's top drug assessment panel in May have included a long-acting "biobetter" lipegfilgrastim from Teva, a once-weekly HGH injection from Biopartners GmbH, and a smallpox vaccine developed by Bavarian Nordic with funding from the U.S. BioShield program.
The lesson from first-generation biosimilars is that these aren't just small-molecule style copies. They require significant clinical and commercial support to overcome prescriber skepticism. For those lining up to tap into the next-generation opportunity, biosimilars represent a new kind of innovation, where the novelty lies in a drug's value-focused pricing, quality, cost-effective production, and in peripherals such as support-services and means of delivery. Although biosimilar market dynamics will vary from molecule to molecule, this emphasis on price and value rather than scientific breakthrough exemplifies a new definition of innovation in the biopharma sector.
- Therapeutic Areas
- Biopartners Holdings AG
- Western Europe
- Parent & Subsidiaries
- Bioton SA
- Senior Management
Conrad Savoy, CEO
Philippe Tremml, PhD, Head, Bus. Dev.
Sandro Gabaglio , Head, Fin. & Admin.
Cornelius Sobel, PhD, CSO
- Contact Info
Phone: (41) 766 20 80
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.